Tg511-13-01: A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC

Cancer - Brain
  1. Is the subject between 18 years old and 80 years old inclusive?
  2. Has the subject undergone at least one prior surgical gross-total or subtotal tumor resection with histologic confirmation of Grade III or IV glioma and a course of postoperative radiation therapy with concurrent temozolomide?
  3. Does the subject have a single, enhancing tumor recurrence/progression that is less than or equal to 8 cm in its greatest dimension?

Please contact us for a complete list of eligibility criteria.

Tiffany Pearce